Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GIP as a potential therapeutic agent?

J J Meier1, M A Nauck

  • 1Larry Hillblom Islet Research Center, UCLA School of Medicine, Los Angeles, CA 90095, USA. jmeier@mednet.ucla.eu

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|January 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucagon-like peptide 1 (GLP-1).

Molecular metabolism·2019
Same author

No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects.

Peptides·2019
Same author

Adaptive changes in pancreas post Roux-en-Y gastric bypass induced weight loss.

Diabetes/metabolism research and reviews·2018
Same author

[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].

Der Internist·2017
Same author

A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers.

Diabetic medicine : a journal of the British Diabetic Association·2017
Same author

[Cardiovascular effects of liraglutide therapy in patients with type 2 diabetes : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)].

Der Internist·2017
Same journal

Determinants of Infant Participation and Non-Participation in Primary Prevention Trials.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Inflammatory Profile of Lipedema: A Comparative Evaluation with Obese and Normal-weight Women.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Comparative Effects of Experimental Diabetes Mellitus and Glucocorticoid-Induced Hypercortisolemia on Pancreatic and Adrenal Endocrine Architecture: A Pathological Study in Rats.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Psychiatric Symptoms in Women with Mild Autonomous Cortisol Secretion Versus Non-Functioning Adrenal Adenomas: A Cross-Sectional Study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Antisemitism as a Chronic Cardiometabolic, Endocrine, and Glutamatergic Stressor Requiring Psychometric Monitoring.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Severe Acute Respiratory Syndrome Coronavirus-2 Infection and New Changes in Thyroid Function Parameters during Hospitalization and Follow-up.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
See all related articles

Glucose-dependent insulinotropic polypeptide (GIP) shows limited therapeutic potential for type 2 diabetes due to absent insulinotropic effects in patients. GIP antagonism is explored for obesity, but risks glucose homeostasis disruption.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) enhance meal-stimulated insulin secretion.
  • GIP's insulinotropic effect is diminished in type 2 diabetes, and its native form has poor pharmacokinetics.
  • GIP receptor antagonists are investigated for obesity, supported by mouse studies, but may disrupt glucose homeostasis.

Purpose of the Study:

  • To evaluate the therapeutic potential of GIP and its analogues for type 2 diabetes.
  • To assess the viability of GIP antagonism as an anti-obesity strategy.

Main Methods:

  • Review of existing literature on GIP function, analogues, and receptor antagonism.
  • Analysis of GIP's role in glucose metabolism and lipid physiology.

Related Experiment Videos

  • Examination of preclinical data, including GIP receptor knock-out mouse models.

    • Main Results:

    • GIP analogues have not achieved glucose normalization in type 2 diabetes patients.
    • GIP receptor antagonism in mice confers protection against diet-induced obesity.
    • Eliminating GIP signaling may negatively impact postprandial insulin secretion and glucose balance.

    Conclusions:

    • Current GIP-based strategies for type 2 diabetes are limited by GIP resistance.
    • While GIP antagonism shows promise for obesity, potential adverse effects on glucose homeostasis require careful consideration.
    • Neither augmenting nor antagonizing GIP action are established therapeutic alternatives for type 2 diabetes or obesity at present.